Gerresheimer is an innovative system and solution provider and global partner for the pharma, biotech and cosmetics industries. The company offers a comprehensive portfolio of pharmaceutical packaging, drug delivery systems, medical devices and digital solutions. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. With around 13,600 employees and over 40 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. | Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The company offers a comprehensive portfolio of pharmaceutical containment solutions, drug delivery systems and medical devices as well as solutions for the health industry. The product range includes digital solutions for therapy support, medication pumps, syringes, pens, auto-injectors and inhalers as well as vials, ampoules, tablet containers, infusion, dropper and syrup bottles and more. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. With 35 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. With around 12,000 employees, the company generated revenues of around €2bn in 2023. Gerresheimer AG is listed in the MDAX on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6). www.gerresheimer.com | Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The Group offers a comprehensive portfolio of drug containment solutions including closures and accessories, as well as drug delivery systems, medical devices and solutions for the health industry. The product range includes digital solutions for therapy support, medication pumps, syringes, pens, auto-injectors and inhalers as well as vials, cartridges, ampoules, tablet containers, infusion, dropper and syrup bottles and more. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. Gerresheimer supports its customers with comprehensive services along the value chain and in addressing the growing demand for enhanced sustainability. With over 40 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. Together with Bormioli Pharma, the Group generated revenues of around EUR 2.4bn in 2024 and currently employs around 13,400 people. Gerresheimer AG is listed in the MDAX on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6). https://www.gerresheimer.com/en/home
EXODUS BIO
EXODUS Bio is a pioneering biotechnology company transforming the future of nanomedicine through its proprietary, automated, and scalable processing system—EXODUS. This cutting-edge technology leverages a dual-membrane nanofiltration platform to efficiently purify exosomes, viruses, and lipid nanoparticles, enabling high-yield, high-purity isolation critical for next-generation therapeutics. At EXODUS Bio, we are committed to unlocking the full potential of biologics and nucleic acid-based therapies by partnering with leading researchers, clinicians, and biopharmaceutical companies worldwide. Through these collaborations, we aim to accelerate the development of safer, more effective delivery systems that drive innovation in RNA medicines, gene therapy, and immunotherapy.
Excelitas Technologies
Excelitas® is a leading provider of advanced, life-enriching technologies that make a difference, serving global market leaders in the life sciences, advanced industrial, next-generation semiconductor and avionics end markets. Headquartered in Pittsburgh, PA, USA, Excelitas is an essential partner in the design, development and manufacture of advanced technologies, offering leading-edge innovation in sensing, detection, imaging, optics and specialty illumination for customers worldwide. Excelitas is at the forefront of addressing many of the relevant megatrends impacting the world today, including precision medicine, industrial automation, artificial intelligence, and connected devices (IoT). Visit booth #3009 to see our Fusion UV® microwave UV curing systems and OmniCure® UV LED and lamp spot and area curing solutions for medical device assembly. Our industry recognized OmniCure spot curing systems feature closed-loop feedback, precise irradiance control and wavelength selection so manufacturers can achieve a controlled and repeatable UV assembly process for improved product yields and maximum reliability.
Evoq
EVOQ Technologies is advancing a function-first paradigm in clinical vision care through its SightGard™ platform, capturing objective retinal and neuro-visual performance using Android mobile device–based diagnostics. Its lead product, the Twilight™ Dark Adaptometer, enables rapid, standardized assessment of dark adaptation and night vision loss, supporting early detection and monitoring of retinal dysfunction across diseases including AMD, diabetic retinopathy, glaucoma, IRDs, and optic neuropathies. EVOQ focuses on repeatable, quantitative biomarkers that identify dysfunction before structural damage is visible, enabling earlier intervention and longitudinal patient monitoring. I-VIVO is EVOQ’s sister company dedicated to in vivo preclinical eye research. It develops and deploys novel structure and function instrumentation to capture high-precision data in small animal models. Capabilities include rodent contact lenses, small animal anesthesia, ERG and multi-spectral fundus imaging.
Diagnosys LLC
Diagnosys LLC offers high-throughput electrophysiology solutions for preclinical testing. The Celeris is our leading rodent and small animal testing platform for electroretinography (ERG). With Celeris, you can examine the function of each cell type along the visual pathway. Diagnosys also makes clinical systems that assist with diagnosing, monitoring, screening, and monitoring various ophthalmic conditions. Presently, our full-field stimulus test (FST) is being used as an endpoint in IRD therapy clinical trials. By popular demand, we expanded our clinical trial services to cover all phases of clinical trials. This includes initial consultation, setup, training, and expert data interpretation.
DGH Technology, Inc.
DGH Technology is the acknowledged worldwide leader for ultrasonic ophthalmic equipment. Our instruments—Pachymeters, A-Scans, B-Scans, and UBM—have been setting standards for reliability and ease of use for over 40 years. All DGH products are proudly made in the USA. | DGH Technology is the acknowledged worldwide leader for ultrasonic ophthalmic equipment. Our instruments: Pachymeters, A-Scans, B-Scans, and UBMs have set standards for accuracy, reliability and ease of use. DGH products are proudly made in the USA. Serving eye care professionals for over 40 years.